REPLIGEN CORP Increase (Decrease) in Other Noncurrent Assets
REPLIGEN CORP (RGEN) reported Increase (Decrease) in Other Noncurrent Assets of -$1.89 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentAssets · last filed 2026-07-29
- REPLIGEN CORP increase (decrease) in other noncurrent assets for the quarter ending 2026-06-30 was -$1.87M, a 641.45% decline year-over-year.
- REPLIGEN CORP increase (decrease) in other noncurrent assets for the quarter ending 2026-03-31 was -$26.00K, a 102.16% decline year-over-year.
- REPLIGEN CORP increase (decrease) in other noncurrent assets for the quarter ending 2025-12-31 was -$167.00K, a 1384.62% decline year-over-year.
- REPLIGEN CORP increase (decrease) in other noncurrent assets for the quarter ending 2025-09-30 was $180.00K.
- REPLIGEN CORP increase (decrease) in other noncurrent assets for fiscal 2025 was $1.56M.
- REPLIGEN CORP increase (decrease) in other noncurrent assets for fiscal 2024 was -$471.00K, a 202.17% decline from fiscal 2023.
- REPLIGEN CORP increase (decrease) in other noncurrent assets for fiscal 2023 was $461.00K.
- REPLIGEN CORP increase (decrease) in other noncurrent assets for fiscal 2020 was $281.00K, a 325.76% increase from fiscal 2019.
| Period end | Increase (Decrease) in Other Noncurrent Assets 3 month | Increase (Decrease) in Other Noncurrent Assets 6 month | Increase (Decrease) in Other Noncurrent Assets 9 month | Increase (Decrease) in Other Noncurrent Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | -$1.89M 10-Q · filed 2026-07-29 | -$2.06M derived: sum of 3 quarters · filed 2026-07-29 | -$1.88M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | -$26.00K 10-Q · filed 2026-05-06 | -$193.00K derived: sum of 2 quarters · filed 2026-05-06 | -$13.00K derived: sum of 3 quarters · filed 2026-05-06 | $332.00K derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | -$167.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $13.00K derived: sum of 2 quarters · filed 2026-02-26 | $358.00K derived: sum of 3 quarters · filed 2026-07-29 | $1.56M 10-K · filed 2026-02-26 |
| 2025-09-30 | $180.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $525.00K derived: sum of 2 quarters · filed 2026-07-29 | $1.73M 10-Q · filed 2025-11-04 | $1.74M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $345.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $1.55M 10-Q · filed 2026-07-29 | $1.56M derived: sum of 3 quarters · filed 2026-07-29 | $1.44M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $1.20M 10-Q · filed 2026-05-06 | $1.22M derived: sum of 2 quarters · filed 2026-05-06 | $1.09M derived: sum of 3 quarters · filed 2026-05-06 | $1.05M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$107.00K derived: sum of 2 quarters · filed 2026-02-26 | -$151.00K derived: sum of 3 quarters · filed 2026-02-26 | -$471.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | -$120.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$164.00K derived: sum of 2 quarters · filed 2025-11-04 | -$484.00K 10-Q · filed 2025-11-04 | -$730.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$44.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$364.00K 10-Q · filed 2025-08-07 | -$610.00K derived: sum of 3 quarters · filed 2026-02-26 | |
| 2024-03-31 | -$320.00K 10-Q · filed 2025-04-29 | -$566.00K derived: sum of 2 quarters · filed 2026-02-26 | ||
| 2023-12-31 | -$246.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $461.00K 10-K · filed 2026-02-26 | ||
| 2023-09-30 | $707.00K 10-Q · filed 2024-11-18 | |||
| 2020-12-31 | $281.00K 10-K · filed 2021-02-24 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $1.00K derived: sum of 2 quarters · filed 2021-02-24 | $66.00K 10-K · filed 2021-02-24 | |
| 2019-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $66.00K 10-Q · filed 2019-10-31 | ||
| 2019-06-30 | $65.00K 10-Q · filed 2019-08-01 | |||
| 2018-09-30 | $107.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $1.35M 10-Q · filed 2019-10-31 | ||
| 2018-06-30 | $1.24M 10-Q · filed 2019-08-01 | |||
| 2017-09-30 | -$50.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $704.00K 10-Q · filed 2018-11-01 | ||
| 2017-06-30 | $754.00K 10-Q · filed 2018-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |